CoChat

Sub-anesthetic and anesthetic ketamine produce different long-lasting behavioral phenotypes (24 h post-treatment) via inducing different brain-derived neurotrophic factor (BDNF) expression level in the hippocampus

Wu, Chunhui, Wang, Yu, He, Yang, Wu, Song, Xie, Zhifei, Zhang, Jian, Shen, Jingshan, Wang, Zhen, He, Ling · 2020 · Neurobiology of Learning and Memory
Cited by 51

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Abstract

Clinical and preclinical researches have shown that sub-anesthetic ketamine elicits sustained antidepressant effects for up to 1-2 weeks. Pharmacokinetics studies (t1/2 = 23 min) in mice showed no ketamine residue at 24 h after sub-anesthetic or anesthetic ketamine administration. Therefore, this study aims to reveal the mechanism underlying these different biological functions at 24 h after sub-anesthetic and anesthetic ketamine treatment. First, at the animal behavioral level, we found that sub-anesthetic ketamine induced antidepressant and anxiolytic effects while anesthetic ketamine induced depressive-like phenotypes and cognitive impairment. Second, we examined the correlation between behavior phenotype and protein expression, and found that the Brain-derived neurotrophic factor (BDNF) level is oppositely regulated by sub-anesthetic and anesthetic ketamine. Sub-anesthetic ketamine significantly increased the BDNF level, correlating to antidepressant effects; whereas anesthetic dose reduced BDNF expression in the hippocampus, correlating to depressive-like behaviors, anxiety-like behaviors and cognitive impairment. Third, the antidepressant effects of sub-anesthetic ketamine were prevented by pre-treatment of ANA-12, a Tropomyosin receptor kinase B (TrkB) inhibitor. Thus, we conclude that BDNF may be the key factor underlying antidepressant and anxiolytic effects of sub-anesthetic ketamine at 24 h after treatment. These results may shed light on future studies and the development of long-lasting anti-depressant drugs and therapies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.nlm.2019.107136

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 18 references

Research works printed but not linked: 27

  1. Andrade, 2017, Ketamine for depression, 4. In what dose, at what rate, by what route, for how long, and at what frequency?, The Journal of Clinical Psychiatry, 78, e852, 10.4088/JCP.17f11738 · DOI · Paper page
  2. Ates-Alagoz, 2013, NMDA receptor antagonists for treatment of depression, Pharmaceuticals, 6, 480, 10.3390/ph6040480 · DOI · Paper page
  3. Berman, 2000, Antidepressant effects of ketamine in depressed patients, Biological Psychiatry, 47, 351, 10.1016/S0006-3223(99)00230-9 · DOI · Paper page
  4. Carspecken, 2018, Ketamine anesthesia does not improve depression scores in electroconvulsive therapy: A randomized clinical trial, Journal of Neurosurgical Anesthesiology, 1
  5. Chang, 2016, Major depressive disorder induced by chronic ketamine abuse: A case report, The Primary Care Companion for CNS Disorders, 18
  6. Cruz, 2009, Toluene has antidepressant-like actions in two animal models used for the screening of antidepressant drugs, Psychopharmacology, 204, 279, 10.1007/s00213-009-1462-2 · DOI
  7. de Oliveira, 2009, Different sub-anesthetic doses of ketamine increase oxidative stress in the brain of rats, Progress in Neuro-Psychopharmacology and Biological Psychiatry, 33, 1003, 10.1016/j.pnpbp.2009.05.010 · DOI
  8. Fraga, 2013, Ketamine alters behavior and decreases BDNF levels in the rat brain as a function of time after drug administration, Revista Brasileira de Psiquiatria, 35, 262, 10.1590/1516-4446-2012-0858 · DOI · Paper page
  9. Garcia, 2008, Acute administration of ketamine induces antidepressant-like effects in the forced swimming test and increases BDNF levels in the rat hippocampus, Progress in Neuro-Psychopharmacology and Biological Psychiatry, 32, 140, 10.1016/j.pnpbp.2007.07.027 · DOI · Paper page
  10. Gibson, 2004, Mitochondrial Enzymes and endoplasmic reticulum calcium stores as targets of oxidative stress in neurodegenerative diseases, Journal of Bioenergetics and Biomembranes, 6
  11. Henley, 2016, Synaptic AMPA receptor composition in development, plasticity and disease, Nature Reviews Neuroscience, 17, 337, 10.1038/nrn.2016.37 · DOI · Paper page
  12. Iwata, 1997, Different effects of oxidative stress on activation of transcription factors in primary cultured rat neuronal and glial cells, Molecular Brain Research, 50, 213, 10.1016/S0169-328X(97)00190-3 · DOI
  13. Krystal, 1994, Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses, Archives of General Psychiatry, 51, 199, 10.1001/archpsyc.1994.03950030035004 · DOI · Paper page
  14. Kudoh, 2002, Small-dose ketamine improves the postoperative state of depressed patients, Anesthesia & Analgesia, 95, 114, 10.1097/00000539-200207000-00020 · DOI · Paper page
  15. Lara, 2013, Antidepressant, mood stabilizing and procognitive effects of very low dose sublingual ketamine in refractory unipolar and bipolar depression, The International Journal of Neuropsychopharmacology, 16, 2111, 10.1017/S1461145713000485 · DOI · Paper page
  16. Li, 2015, Drug pharmacokinetics determined by real-time analysis of mouse breath, Angewandte Chemie International Edition, 54, 7815, 10.1002/anie.201503312 · DOI
  17. Ma, 2013, Long-lasting antidepressant action of ketamine, but not glycogen synthase kinase-3 inhibitor SB216763, in the chronic mild stress model of mice, PLoS ONE, 8, e56053, 10.1371/journal.pone.0056053 · DOI · Paper page
  18. Mao, 2012, Anti-depressant-like effect of peony: A mini-review, Pharmaceutical Biology, 50, 72, 10.3109/13880209.2011.602696 · DOI
  19. Noda, 2000, Repeated phencyclidine treatment induces negative symptom-like behavior in forced swimming test in mice imbalance of prefrontal serotonergic and dopaminergic functions, Neuropsychopharmacology, 23, 375, 10.1016/S0893-133X(00)00138-X · DOI
  20. Pitsikas, 2009, Pre-training administration of anesthetic ketamine differentially affects rats’ spatial and non-spatial recognition memory, Neuropharmacology, 57, 1, 10.1016/j.neuropharm.2009.03.015 · DOI
  21. Seillier, 2009, Evaluation of NMDA receptor models of schizophrenia: Divergences in the behavioral effects of sub-chronic PCP and MK-80, Behavioural Brain Research, 6
  22. Singh, 2016, Intravenous esketamine in adult treatment-resistant depression: A double-blind, double-randomization, placebo-controlled study, Biological Psychiatry, 80, 424, 10.1016/j.biopsych.2015.10.018 · DOI · Paper page
  23. Venâncio, 2015, Acute ketamine impairs mitochondrial function and promotes superoxide dismutase activity in the rat brain, Anesthesia & Analgesia, 120, 9, 10.1213/ANE.0000000000000539 · DOI
  24. Wang, 2011, A single subanesthetic dose of ketamine relieves depression-like behaviors induced by neuropathic pain in rats, Anesthesiology, 115, 812, 10.1097/ALN.0b013e31822f16ae · DOI · Paper page
  25. Zarate, 2015, Ketamine for depression: Evidence, challenges and promise, World Psychiatry, 14, 348, 10.1002/wps.20269 · DOI · Paper page
  26. Zarate, 2006, A Randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression, Archives of General Psychiatry, 63, 9, 10.1001/archpsyc.63.8.856 · DOI · Paper page
  27. Zou, 2006, CREB and NF-κB transcription factors regulate sensitivity to excitotoxic and oxidative stress induced neuronal cell death, Cell Mol Neurobiol, 26, 383, 10.1007/s10571-006-9045-9 · DOI · Paper page

Cited by

See all 51

Metadata

Authors
Wu, C., Wang, Y., He, Y., Wu, S., Xie, Z., Zhang, J., Shen, J., Wang, Z., & He, L.
Venue
Neurobiology of Learning and Memory
Publisher
Elsevier BV
Published
2020-01
Volume
167
Pages
107136
ISSN
1074-7427 (ISSN-L)
OpenAlex
W2991906941
Cited by
51
References
18
FWCI
1.83
Type
journal article
Language
en
Open access
closed
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Funders
  • Chinese Academy of Sciences (XDA12040105)
  • Science and Technology Commission of Shanghai Municipality (17431900500)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Sub-anesthetic and anesthetic ketamine produce different long-lasting behavioral phenotypes (24 h post-treatment) via inducing different brain-derived neurotrophic factor (BDNF) expression level in the hippocampus. https://app.cochat.ai/papers/10.1016/j.nlm.2019.107136
The paper
Wu, C., Wang, Y., He, Y., Wu, S., Xie, Z., Zhang, J., Shen, J., Wang, Z., & He, L. (2020). Sub-anesthetic and anesthetic ketamine produce different long-lasting behavioral phenotypes (24 h post-treatment) via inducing different brain-derived neurotrophic factor (BDNF) expression level in the hippocampus. Neurobiology of Learning and Memory. https://doi.org/10.1016/j.nlm.2019.107136

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.